Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 4, 2011, Pages 929-933

  Song, Tao ^a   Zhang, Xu ^a   Wang, Chunyang ^a   Wu, Yiguang ^a   Dong, Jun ^a   Gao, Jiangping ^a   Cai, Wei ^a   Hong, Baofa ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

COX 2; Human bladder carcinoma; MiR 143

Indexed keywords

EID: 84863012523     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bartel DP (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-33.
2. Buckman SY, Gresham A, Hale P, et al (1998). COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis, 19, 723-729.
3. Calin GA, Sevignani C, Dumitru CD, et al (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA, 101, 2999-3004.
4. DeVere White RW, Vinall RL, Tepper CG, et al (2009). MicroRNAs and their Potential for Translation in Prostate Cancer. Urol Oncol, 27, 307-11.
5. Dyrskjøt L, Ostenfeld MS, Bramsen JB, et al (2009). Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res, 69, 4851-60.
6. Filipowicz W, Bhattacharyya SN, Sonenberg N (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet, 9, 102-14.
7. Gangwar R, Mandhani A, Mittal RD (2011). Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. Surgery, 149, 126-34.
8. Garzon R, Fabbri M, Cimmino A, et al (2006). MicroRNA expression and function in cancer. Trends Mol Med, 12, 580-7.
9. Hammam OA, Aziz AA, Roshdy MS, et al (2008). Possible role of cyclooxygenase-2 in schistosomal and non-schistosomalassociated bladder cancer. Medscape J Med, 10, 60.
10. Lamm DL, Riggs DR, Traynelis CL et al (1995). Apparent failure of current intravesical chemotherapy prophylaxis to influence the long term course of superficial transitional cell carcinoma of the bladder. J Urol, 153, 1444-50.
11. Li C, Feng Y, Coukos G, et al (2009). Therapeutic microRNA strategies in human cancer. AAPS J, 11, 747-57.
12. Li S, Fu H, Wang Y, et al (2009). MicroRNA-101 Regulates Expression of the v-fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) Oncogene in Human Hepatocellular Carcinoma. Hepatology, 49, 1194-202.
13. Lokeshwar VB, Soloway MS (2001). Current bladder tumor tests: does their projected utility fulfill clinical necessity?. J Urol, 165, 1067-1077.
14. Lokeshwar VB, Habuchi T, Grossman HB, et al (2005). Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology, 66, 35-63.
15. Wang X, Colby JK, Rengel RC, et al (2009). Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces the expression of immune- and cell proliferationrelated genes. Mol Carcinog, 48, 1-13.
16. Ratliff TL (2005). Urine markers for bladder cancer surveillance: a systematic review. Eur Urol, 174, 2065-6.
17. Sexton WJ, Wiegand LR, Correa JJ, et al (2010). Bladder Cancer: A Review of Non-Muscle Invasive Disease. Cancer Control, 17, 256-68.
18. Shahjee HM, Koch KR, Guo L, et al (2010). Antiproliferative factor decreases Akt phosphorylation and alters gene expression via CKAP4 in T24 bladder carcinoma cells. J Exp Clin Cancer Res, 29, 160.
19. Shan Y, Wu K, Wang W, et al (2009). Sulforaphane downregulates COX-2 expression by activating p38 and inhibiting NF-kappaB-DNA-binding activity in human bladder T24 cells. Int J Oncol, 34, 1129-34.
20. Singh PB, Kumar A, Das SK, et al (2010). Management of superficial bladder carcinoma: Time to rethink the treatment strategies in the era of orthotopic neo-bladder. Saudi J Kidney Dis Transpl, 21, 881-5.
21. Song T, Xia W, Shao N, et al (2010). Differential miRNA Expression Profiles in Bladder Urothelial Carcinomas. Asian Pac J Cancer Prev, 11, 905-11.
22. Sternberg CN (2000). Gemcitabine in bladder cancer. Semin Oncol, 27, 31-9.
23. Strillacci A, Griffoni C, Valerii MC, et al (2010). RNAi-Based Strategies for Cyclooxygenase-2 Inhibition in Cancer. J Biomed Biotechnol, 828045.
24. Trang P, Weidhaas JB, Slack FJ (2008). MicroRNAs as potential cancer therapeutics. Oncogene, 27, 52-7.
25. Yu L, Chen XJ, Shi PQ, et al (2008). Expression of cyclooxygenase-2 in bladder transitional cell carcinoma and the significance thereof. Zhonghua Yi Xue Za Zhi, 88, 2683-4.
26. Yu Q, Zhang K, Wang X, et al (2010). Expression of transcription factors snail, slug, and twist in human bladder carcinoma. J Exp Clin Cancer Res, 29, 119.